CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it will present interim data at the annual meeting of the American Society for Clinical Oncology (ASCO) on its Phase I clinical trial of Azedra (Ultratrace™ Iobenguane I 131) in patients with malignant pheochromocytoma/paraganglioma. The trial is part of the company’s program to develop Azedra for the treatment of neuroendocrine cancers.
